Overview Financials News + Filings Key Docs Ownership Insiders
|
Inhibikase Therapeutics, Inc.
|
|
Operating Efficiency |
|
|
|
|
Annual |
|
In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 |
| Source | Source | Source | Source | Source |
Turnover Ratios |
Asset turnover | 0.0 | 0.1 | 0.1 | 0.8 | |
|
Returns on Capital |
ROIC (excluding intangibles) | -254.3% | -301.2% | -48.7% | | |
ROIC (including intangibles) | -124.5% | 4972.6% | -13.9% | 131.4% | 234.5% |
ROE | -86.2% | -38.4% | -14.4% | 121.5% | 272.8% |
ROA | -72.7% | -34.8% | -9.5% | 3485.4% | -74.6% |
|
Cash Conversion Cycle |
Days sales outstanding | 0.0 | 0.0 | 0.0 | 0.0 | 42.7 |
Days payables outstanding | | | 178.6 | 143.2 | 95.5 |
Cash conversion cycle | | | -178.6 | -143.2 | -52.8 |
|